GlassScriptPhysician profile
Allison S Kavanagh
NPI 1275869281
$2,753.41
in general payments reported to CMS, 2019-2025
35 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $351 · 2022: $538 · 2023: $198 · 2024: $598 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $233.73 | 2021-2025 | Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $209.38 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $208.45 | 2021-2025 | Watchman Flx, Resonate El Icd Vr |
| Pfizer INC. | $178.74 | 2021-2025 | |
| Cvrx, INC. | $177.48 | 2021-2025 | Barostim Neo System |
| Abbott Laboratories | $173.34 | 2025 | Navitor, Mitraclip |
| Biosense Webster, INC. | $159.93 | 2025 | Carto 3 |
| Medtronic, INC. | $157.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $124.29 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.43 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $99.94 | 2022-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $85.88 | 2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $77.40 | 2022-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $76.81 | 2021-2025 | Wainua, Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $69.20 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stereotaxis INC | $64.67 | 2021 | |
| Kestra Medical Technology Services, INC. | $50.19 | 2025 | Assure Wcd |
| Tactile Systems Technology INC | $47.03 | 2025 | Nimbl, Flexitouch Plus |
| Novo Nordisk INC | $46.28 | 2022 | |
| Impulse Dynamics (USA) INC. | $41.79 | 2022 | |
| Amgen INC. | $38.30 | 2024 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $38.28 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $33.72 | 2025 | Dupixent |
| Philips North America LLC | $30.87 | 2024 | (Ck4) Mcot |
| Atricure, INC. | $26.67 | 2025 | Synergy Ablation System |
| Lilly USA, LLC | $25.34 | 2024 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $25.28 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.03 | 2024 | |
| Altathera Pharmaceuticals LLC | $20.85 | 2024 | Sotalol Hydrochloride |
| Convatec INC. | $20.20 | 2025 | |
| Scpharmaceuticals INC. | $18.14 | 2025 | |
| Innovation Technologies INC | $15.56 | 2025 | Irrisept |
| Baxter Healthcare | $14.63 | 2024 | Perclot |
| Kiniksa Pharmaceuticals, LTD. | $14.49 | 2023 | Arcalyst |
| Amarin Pharma, INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Kavanagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.